2008). GH transgenic coho salmon on a restricted ration have the same plasma IGF-I levels and liver 22 IGF-I mRNA expression as wild-type fish, despite highly increased plasma GH (Raven et al., 2008) . 23
This study system can be used to disentangle the impacts of GH from its influence on feed intake and 24 growth rate. To date however, there are no published reports addressing the impact of GH 25 transgenesis on the response of skeletal muscle to immune challenge. 26
27
The aim of the current study was to characterise gene expression regulation linking growth to immune 28 function within the skeletal muscle of coho salmon, focussing on the GH and IGF systems. We 29 contrasted transcriptional responses of genes from both pathways, in addition to selected markers of 30 immune and muscle growth status, to immune stimulation in three experimental groups, comparing 31 wild-type animals with a GH transgenic strain achieving either maximal or supressed growth by ration 32 manipulation. Our findings reveal a disruption to immune function and the regulation of growth-33 immune cross-talk in muscle of GH transgenic animals, with implications for the health of rapidly 34 growing fish strains used in aquaculture. 
MATERIALS AND METHODS 3 4

Experimental design 5
Experiments on coho salmon were performed at Fisheries and Oceans Canada (DFO), West 6 Vancouver, British Columbia, Canada. This facility is designed to prevent the escape of transgenic 7 fish to the natural environment. All work was done in accordance with guidelines of the Canadian 8
Council on Animal Care, under a permit (#12-017) from the DFO's Pacific Regional Animal Care 9
Committee. All studied fish were initially maintained under common garden conditions (4,000L 10 tanks supplied with 10.5 ± 1 ºC aerated well water, natural photoperiod, at a density <5 kg/m 3 ) and 11 fed a commercial diet (Skretting Ltd., Canada) twice daily at 09:00 and 15:00 (3% of body weight 12 per day). Three experimental groups were generated after Oakes et al. 2007 and Raven et al. 2008: (i) 13
19-month-old wild-type animals fed to satiation throughout ontogeny (wild-type: 'WT'), (ii) 6-14 month-old GH transgenic animals fed to satiation throughout ontogeny (transgenic full ration: 'TF'), 15 and (iii) 17-month-old GH transgenic animals fed to the WT satiety level throughout ontogeny 16 (transgenic restricted ration: 'TR'). Using fish of different ages was necessary to standardize the 17 confounding effects of body size, owing to different growth rates among the groups. The WT group 18 Laboratories Ltd., Vancouver, BC, Canada; buffered in 400mg/L sodium bicarbonate) after prior 35 sedation using Aquacalm (1mg/L; Syndel Laboratories Ltd., Vancouver, BC, Canada). For each 36 group, 10 fish were randomly sampled 6h and 30h post-treatment, done at the exact same time of day 1 for both time points. A panel of tissues, namely skeletal muscle, intestine, liver, head-kidney and 2 spleen, were rapidly team sampled. For all tissues except skeletal muscle, samples were fixed in 3 RNAlater™ (ThermoFisher Scientific) overnight at 4ºC, and stored at -80ºC. For skeletal muscle, the 4 samples were split, with half fixed in RNAlater as described above, and the other half flash frozen on 5 dry ice. For the current study, the skeletal muscle samples were shipped on dry ice to the School of 6
Biological Sciences, University of Aberdeen, UK, where samples were stored at -70ºC until analysis. 7
Samples fixed in RNAlater were used for all molecular analyses described below (n=5 fish per 8 group, per treatment; 45 samples). 9
10
Primers for quantitative PCR 11
Details of primers pairs for 47 quantitative PCR (qPCR) assays performed in the study are provided 12
in Table S1 , including citations to previously published primers. Coho salmon genes of interest were 13 initially acquired using Atlantic salmon and rainbow trout orthologues acquired from the NCBI 14 the current paper was in preparation, a high-quality genome was released for coho salmon (NCBI 18 accession; GCA_002021735.1). Hence, a larger pool of gene models became available, which were 19 used to check all coho salmon sequences targeted by qPCR; where possible, we report coho-specific 20 accession numbers for all gene targets (Table S1 ). For most IGF system genes, we found that 21 published primers from Atlantic salmon (Macqueen et al., 2013 ) and rainbow trout (Alzaid et al., 22 2016a, 2016b) were conserved in coho salmon. New primer pairs were designed for IGFBP-1A2 and 23 IGFBP-5B1 owing to significant mismatches between published primers and coho salmon. 24
Salmonid-specific genes encoding GH are known for salmonids (previously named GH1 and GH2) 25 Table S1 ). We initially tested primers conserved across both GH duplicates and detected 27 limited muscle transcript expression: since this primer pair binds both genes equally, we concluded 28 that neither GH duplicate was sufficiently expressed to warrant design of additional primers. A past 29 study identified salmonid-specific duplicates of GHR (GHR1 and GHR2), including in coho salmon 30 (Very et al. 2005 ), for which we designed new primer pairs that bind divergent regions among the 31 duplicates (Table S1 ). Additional primers were used for marker genes known to be strongly 32 upregulated by immune stimulation or to be directly involved in muscle growth and development 33 Within GenEx, efficiency-corrected, normalized arbitrary transcript levels were placed on a relative 11 scale that was quantitatively comparable across different genes. 12
13
Statistics 14
Statistical analyses were performed in Minitab v.18 (Minitab Inc.). Differences in baseline gene 15 transcript levels among fish groups for the control animals (PBS-injected) were identified using one-16 way ANOVA, with Tukey's post-hoc test to reveal significant pair-wise differences among groups 17 
RESULTS
31
32
GH transgenesis alters baseline expression of GH and IGF system genes in skeletal muscle 33 34
We first assayed the baseline mRNA levels of all tested GH and IGF pathway genes in the muscle of 35 unstimulated control fish for the three experimental groups ( Fig. 1; Table 1 ). For the mRNAs 36 encoding hormones, GH was expressed at low levels in all groups, IGF-I expression was not different 37 across the groups, while IGF-II expression was significantly elevated (by ~2.3 fold) in TR vs. WT 1 ( Fig. 1A ; Table 1 ). IGF-II levels were substantially (~20 fold) higher than IGF-I in all groups ( Table  2 1). Among the assayed receptors, GHR1 transcript levels were significantly lower in TF vs. WT and 3 TF vs. TR comparisons (by ~4.5 and 2.5 fold, respectively), whereas GHR2 expression was not 4 significantly different across groups ( Fig. 1B; Table 1 ). Expression of IGF1R-a2 was higher than 5 other IGF1R family genes (i.e. IGF1R-a1 and IGF1R-b) in all groups, and significantly higher in TF 6 vs. WT, by ~2.4 fold ( Fig. 1C ; Table 1 ). The expression of four out of eleven expressed IGFBP family 7 member genes differed significantly between the three groups ( Table 1) . No muscle expression was 8
detected for IGFBP-1B1, -1B2, -2B1, -2B2, -3B1, -3B2, -6A1 and -6A2. IGFBP-1A2 transcript levels 9
were significantly higher (by ~3.8 fold) in TF vs. WT, but were not significantly different comparing 10 TF and TR, despite showing a trend of being higher in the former (Fig. 1D) . Conversely, IGFBP-3A1, 11
IGFBP-5B1 and IGFBP-6B2 were each most highly expressed in the TR group, and always 12 significantly higher than WT (and significantly higher than TF for IGFBP-5B1 only) ( Fig. 1E-G ; 13 Table 1 ). For the tested markers of muscle growth status, most were not differentially expressed 14 across groups, including FBXO32 (Tacchi et al., 2010), which encodes an E3-ubiquitin ligase 15 involved in structural protein turnover, TNNI2 and MYL1, which encode sarcomere proteins and 16
MyoG, a transcription factor for myogenic differentiation (Table 1) . However, transcript levels of 17
MyoD1a (Macqueen and Johnston, 2006), a transcription factor for myogenic determination and 18 differentiation, were significantly elevated in TF vs. WT ( Fig. 1H ; Table 1) . 19
20
GH transgenesis alters skeletal muscle immune gene expression 21 22
To assess skeletal muscle responses to PGN, we measured transcript levels for markers of pro-23 inflammatory cytokines (TNFα, IL-1β, and IL-8) and acute phase proteins (SAA and HAMP) ( Fig. 2A ; 24 Table S2 ) after Castro et al. 2015 . A response to PGN was detected in each group, evidenced by a 25 significant induction of all tested marker genes barring TNFα in TF ( Fig. 2A ; Table S2 ). The lack of 26 TNFα response in TF was coupled to a respective 5.4 and 4.1-fold higher baseline expression vs. WT 27 and TR ( Fig. 2A ; Table S2 ). In addition, the magnitude of observed responses of TNFα, IL-1β and IL-28 8 was distinct among the fish groups; being highest in WT, intermediate in TR and lowest or non-29 existent in TF, leading to a significant treatment-x-group interaction ( Fig. 2A ; Table S2 ). In contrast, 30
SAA and HAMP showed a highly significant induction in all groups, without any treatment-x-group 31 interaction ( Fig. 2A ; Table S2 ). 32
33
To assess skeletal muscle responses to Poly:IC, we measured transcript levels for markers of 34 cytokines and proteins involved in the antiviral response (IFN-a, γ-IP, Mx, LMP2 and RSAD2) ( Table S2 ). The responses of these genes showed a striking and consistent 37 difference among groups, with between ~17 and 470 fold induction across the five genes in WT, 1 compared to between ~1.6 and 34 fold in TR, and no upregulation in TF, leading to a highly 2 significant treatment-x-group interaction ( Fig. 2B ; Table S2 ). 3
4
GH transgenesis alters the responses of GH and IGF system genes to immune stimulation 5 6 PGN altered the expression of several GH and IGF pathway genes, with distinct responses observed 7 among fish groups ( Table 2) . PGN had no effect on the expression of mRNAs encoding GH or IGF 8 ( Table 2 ). Considering the tested receptors, PGN had a significant overall effect on the expression of 9 GHR1, GHR2 and IGF1R-b ( Table 2) . These effects were different among the fish groups for GHR1, 10 where a significant treatment-x-group interaction was observed ( Table 2) ; GHR1 was significantly 11 downregulated in WT by PGN, unchanged in TR, and significantly upregulated in TF by more than 5 12 fold ( Table 2 ). The expression of several IGF-binding proteins was modified by PGN, often with 13 distinct effects among groups ( Table 2) . IGFBP-1A2 was significantly downregulated in TF, which 14 followed a similar trend in TR, and an opposite trend in WT, where the same gene was upregulated 15
(non-significant effect) ( Table 2) . Following a similar trend, IGFBP-3A2 was significantly 16 downregulated in both transgenic groups, while IGFBP-6B2 was significantly downregulated in TR 17 (Table 2) . Considering the marker genes for muscle growth status, we observed no expression 18 responses to PGN for genes encoding sarcomeric proteins along with myoG, while MyoD1a showed a 19 strong and significant downregulation in TF specifically (Table 2) . 20
21
Poly:IC had a major effect on the expression of GH and IGF pathway genes, with many showing 22 distinct responses among wild-type and GH transgenic fish, reflected in significant treatment-x-group 23 interaction effects (Table 3) . Among the tested hormones, IGF-II showed a significant 24 downregulation in both transgenic groups (Table 3) . For the tested receptors, GHR1 was significantly 25 induced in TF, while IGF1R-b showed a significant downregulation in both transgenic groups (Table  26 3). Several IGFBP mRNAs were significantly altered by Poly:IC, with IGFBP-1A2 showing 27 significant upregulation in WT, but significant downregulation in both transgenic groups (Table 3) . A 28 similar pattern was observed for IGFBP-2A, IGFBP-5B2, IGFBP-6B1 and IGFBP-6B2, with 29 significant downregulation in both transgenic groups (Table 3) . Considering the markers of muscle 30 growth status, MyoD1a was significantly downregulated by Poly:IC in TF (Table 3) . and immune function in coho salmon muscle, which is disrupted by GH transgenesis as well as its 7 impacts on growth rate and physiological status. 8 9 Altered expression of GH and IGF system genes by GH transgenesis 10 11
Several GH and IGF system genes, along with muscle growth genes, showed altered expression in GH 12 transgenic coho, often with responses differing among TR and TF groups. We observed a significant 13 elevation of IGF-II and IGFBP-5B1 expression in TR, but not TF, compared to WT. A past study on 14 the same type of coho groups documented a life-long reduction in muscle fibre production rate in TR 15 when compared to both TF and WT, accompanied by downregulation of genes involved in myotube Other molecular markers of myogenesis were altered by GH transgenesis in the TF group specifically, 27 notably an increase in the expression of MyoD1a, which encodes a salmonid duplicate for a 28 transcription factor from the myogenic regulatory factor family, which also includes MyoG 29 (Macqueen et al. 2007 ). This finding points towards differences in myogenic development influenced 30 by growth rate and nutritional status in GH transgenics. A past study showed that MyoD1a and MyoG 31 were co-expressed during development of Atlantic salmon primary muscle cell cultures, each peaking 32 in expression during myogenic differentiation (Bower and Johnston, 2010) . However, in our study, 33
MyoG was not changed by GH transgenesis, in contrast to past reports in coho salmon (Overturf et al. to PGN, the pro-inflammatory cytokines IL-1β, IL-8 and TNFα were strongly induced in WT, 36 confirming the anticipated inflammatory response. While TR and TF groups showed a comparable 37 response, the magnitude of cytokine induction was lower than WT, and particularly attenuated in TF, 1 which failed to upregulate TNF-α ( Fig. 2A, Table S2 ). These findings suggest that the GH transgenic 2 fish have a reduced inflammatory response, particularly when maximal growth rate is being achieved. Several GH and IGF system genes showed altered regulation to immune stimulation in GH 8 transgenics. This effect was particular evident in response to Poly:IC, mirroring the strong attenuation 9 of the antiviral response, and supporting the hypothesis that altered immune function in transgenics is 10 directly influencing growth gene expression and 'normal' cross-talk between immunity and growth. 11 12 However, the observed changes in growth gene expression are complex, and not straightforward to 13 interpret in full. It is also important to remember the baseline levels of gene expression in the different 14 coho groups, when interpreting observed changes in gene regulation. For example, IGF-II was 15 significantly downregulated by Poly:IC in both transgenic groups, but not WT, yet there were no 16 differences in the post-treatment transcript levels comparing any group -hence, IGF-II 17 downregulation reduced expression to the wild-type level. As IGF-II promotes muscle growth (e.g. 18
Ren et al., 2008), this provides evidence that GH transgenics may be suppressing growth signalling to 19
the wild-type level during a viral immune response. However, as IGF-II downregulation was equally 20 evident in both TR and TF groups, the underlying mechanisms must result from GH transgenesis per 21 se, which is less consistent with a scenario where the fast-growing TF group is reallocating available 22 resources to immune function. In a similar respect, mRNAs encoding several IGFBP sub-types 23 (IGFBP-6B2 for both treatments; IGFBP-6B1 for Poly:IC; IGFBP-5B2 for Poly:IC and IGFBP-2A for 24
Poly:IC) showed significant differences in regulation across the fish groups, but had similar mRNA 25 expression levels across all groups after immune mimic treatment. Invariably, this was coupled to 26 downregulation of IGFBP expression in both the GH transgenic groups, suggesting these altered 27 responses to immune stimulation were caused by GH transgenesis, rather than its impact on growth 28 difficult to predict the effects that downregulation of multiple IGFBP subtypes will have in the GH 32 transgenics, both in terms of muscle growth, but also several other metabolic phenotypes known to be 33 regulated by this protein family (Jones and Clemmons, 1995). 34
35
In other cases, patterns of gene expression in GH transgenics were consistent with an upregulation of 36 growth signalling in response to immune challenge, when wild-type fish were downregulating growth. 37
In response to both PGN and Poly:IC, the GH receptor GHR1 was strongly upregulated in TF, and the 1 post-treatment level of GHR1 mRNA in GH transgenics was higher than for the WT group, which 2 downregulated GHR1 (significant effect for PGN only) in response to immune stimulation. As GH 3 receptors are required for GH signalling, these patterns suggest that regulatory mechanisms present in 4 wild-type fish that restrict growth during an immune challenge are altered in GH transgenics when 5 maximal growth is being achieved. Wild-type fish also showed an upregulation of IGFBP-1A2 in 6 response to immune stimulation (significant for Poly:IC), which may serve to restrict IGF signalling 7 by sequestering IGF hormones away from IGF-1R. In GH transgenics, the opposite trend was 8 observed, with downregulation of IGFBP-1A2 mRNA to a level below that of wild-type, which might 9 be expected to comparatively promote growth by increasing IGF availability to IGF-1R. 10
11
We also observed a strong downregulation of IGF1R-b for both GH transgenic groups in response to 12 Poly:IC specifically. As this IGF receptor subtype was expressed at the same levels in the 13 unstimulated fish, this resulted in both GH transgenic groups being expressed at much lower mRNA 14 area is proportional to mean transcript levels (n=5 fish, per group). Two-way ANOVA revealed that 39 all the shown genes were significantly induced (P<0.05) by the immune stimulations (Table S2) and 40
Tukey's post hoc test identified significant changes in gene expression between control and treated 1 fish, shown by asterisks next to accompanying fold-change values (calculated by dividing mean 2 treatment by mean control, n=5 per mean). Full data (means±s.d.) is given in Table S2 . Relative transcript levels (means±s.d, n=5) are shown as arbitrary units normalized to two empirically validated reference genes (RpL13 and ACTB) and are quantitatively comparable across genes and among fish groups. Probability values are from one-way ANOVA testing for an effect of fish group. Different superscript letters highlight significant differences in transcript levels among groups according to Tukey's post-hoc test. The symbol ' ˄ ' shows genes where the data required Box-Cox transformation.
Table 2. Effects of PGN on expression of GH and IGF system genes comparing wild-type to transgenic coho salmon groups
Fold change values (underlined: calculated by dividing the mean control and mean PGN treatment transcript levels, n=5 fish per mean) are given for genes where a significant effect of treatment and a significant treatment-x-group interaction was recorded by two-way ANOVA (the symbol '*' indicates a significant expression change according to Tukeys post-hoc test). For the same genes, relative transcript levels are shown post-PGN treatment (means±s.d, n=5) and represent arbitrary units normalized to two empirically validated reference genes (RpL13 and ACTB) that are quantitatively comparable across genes and among fish groups (different superscript letters highlight significant differences among groups according to Tukeys post-hoc test).
The symbol '˄' shows genes where the data required Box-Cox transformation. The symbol '-' shows genes where a Kruskal-Wallis test was done testing for a treatment effect only. Fold change values (underlined: calculated by dividing the mean control and mean Poly:IC treatment transcript levels, n=5 fish per mean) are given for genes where a significant effect of treatment and a significant treatment-x-group interaction was recorded by two-way ANOVA (the symbol '*' indicates a significant expression change according to Tukeys post-hoc test). For the same genes, relative transcript levels are shown post-Poly:IC treatment (means±s.d, n=5) and represent arbitrary units normalized to two empirically validated reference genes (RpL13 and ACTB) that are quantitatively comparable across genes and among fish groups (different superscript letters highlight significant differences among groups according to Tukeys post-hoc test). The symbol '˄' shows genes where the data required Box-Cox transformation. The symbol '-' shows genes where a Kruskal-Wallis test was done testing for a treatment effect only. 
Gene
P-value treatment
